首页 > 市场调查报告书 > 製药

癌症生物製剂

市场调查报告书

商品编码

1746674

日本癌症免疫疗法市场报告（按疗法类型、应用、最终用户和地区）2025-2033

Japan Cancer Immunotherapy Market Report by Therapy Type, Application, End User, and Region 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 115 Pages | 商品交期: 5-7个工作天内

价格

简介目录

2024年，日本癌症免疫疗法市场规模达75.412亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到144.583亿美元，2025-2033年期间的复合年增长率（CAGR）为7.2%。推动该市场发展的几个重要因素包括癌症发生率的上升、政府的支持性项目以及医疗保险的普及。

癌症是一种以体内某些细胞不受控制地生长并扩散到各部位为特征的疾病。其发展通常与饮酒或吸烟、不健康饮食、暴露于空气污染、缺乏运动等因素有关。癌症患者会面临严重的健康挑战，包括焦虑、忧郁、对死亡的恐惧、疼痛、压力，甚至产生自杀念头。免疫疗法是一种癌症治疗方法，利用抗体结合癌细胞产生的蛋白质并抑制其活性。这种方法有助于增强免疫系统识别和清除体内异常癌细胞的能力。因此，免疫疗法广泛应用于各种癌症的治疗，包括肺癌、乳癌、大肠癌、黑色素瘤、摄护腺癌、头颈癌、甲状腺癌、肾癌、肝癌、子宫颈癌、膀胱癌、卵巢癌和皮肤癌。

日本癌症免疫治疗市场趋势：

在日本市场，若干重要因素正在积极影响癌症免疫疗法产业。主要驱动因素之一是全球癌症病例数量的上升，这归因于不良饮食习惯和接触有害物质。此外，全球民众对多样化癌症治疗方案的认识日益提高，这也促进了市场扩张。此外，癌症免疫疗法的日益普及得益于其与传统抗肿瘤疗法相比，能够延长无恶化存活期 (PFS) 和总存活期 (OS)。医疗保险的普及性和可近性，以及医疗支出的不断增长，为行业投资者带来了诱人的成长前景。此外，对副作用较小的治疗方法的需求日益增长，这与新型免疫疗法获批率的不断提高相一致，并推动了市场成长。各国政府机构和非营利组织正积极推广癌症免疫疗法，并进行以癌症预防为重点的广泛宣传活动。最后，市场受益于癌症治疗技术的持续进步，这些进步正在提高疾病管理策略的效率。这些因素共同促进了日本癌症免疫治疗市场的正向成长轨迹。

日本癌症免疫治疗市场细分：

治疗类型见解：

单株抗体
癌症疫苗
检查点抑制剂
免疫调节剂
其他的

应用程式洞察：

肺癌
乳癌
大肠直肠癌
黑色素瘤
摄护腺癌
头颈癌
其他的

最终用户洞察：

医院
癌症研究中心
诊所
其他的

竞争格局：

市场研究报告也对竞争格局进行了全面的分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪錶板和公司评估象限等竞争分析。此外，报告还提供了所有主要公司的详细资料。

本报告回答的关键问题：

日本癌症免疫治疗市场迄今表现如何？未来几年将如何表现？
COVID-19 对日本癌症免疫治疗市场有何影响？
根据治疗类型，日本癌症免疫治疗市场是如何分類的？
日本癌症免疫治疗市场如何按应用情况划分？
根据最终用户，日本癌症免疫治疗市场是如何分布的？
日本癌症免疫治疗市场的价值链分为哪些阶段？
日本癌症免疫治疗的关键驱动因素和挑战是什么？
日本癌症免疫治疗市场的结构是怎么样的？主要参与者是谁？
日本癌症免疫治疗市场的竞争程度如何？

本报告回答的关键问题：

日本癌症免疫治疗市场迄今表现如何？未来几年将如何表现？
COVID-19 对日本癌症免疫治疗市场有何影响？
根据治疗类型，日本癌症免疫治疗市场是如何分類的？
日本癌症免疫治疗市场如何按应用情况划分？
根据最终用户，日本癌症免疫治疗市场是如何分布的？
日本癌症免疫治疗市场的价值链分为哪些阶段？
日本癌症免疫治疗的关键驱动因素和挑战是什么？
日本癌症免疫治疗市场的结构是怎么样的？主要参与者是谁？
日本癌症免疫治疗市场的竞争程度如何？

Japan cancer immunotherapy market size reached USD 7,541.2 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 14,458.3 Million by 2033, exhibiting a growth rate (CAGR) of 7.2% during 2025-2033. The market is being propelled by several significant factors, including an increasing incidence of cancer cases, supportive government programs, and the widespread accessibility of medical insurance.

Cancer is a medical condition characterized by the uncontrolled growth and spread of certain cells in the body to various parts. Its development is often linked to factors such as alcohol or tobacco consumption, an unhealthy diet, exposure to air pollution, and a lack of physical activity. Individuals affected by cancer can experience significant health challenges, including feelings of anxiety, depression, fear of mortality, pain, stress, and even thoughts of suicide. Immunotherapy is an approach to cancer treatment involving the use of antibodies that bind to and inhibit the activity of proteins produced by cancer cells. This method helps strengthen the immune system's ability to identify and eliminate abnormal cancer cells within the body. Consequently, it finds widespread application in the treatment of various cancer types, including lung, breast, colorectal, melanoma, prostate, head and neck, thyroid, kidney, liver, cervical, bladder, ovarian, and skin cancers.

Japan Cancer Immunotherapy Market Trends:

In the context of the Japanese market, several significant factors are positively impacting the cancer immunotherapy sector. One of the primary drivers is the rising number of cancer cases, attributed to poor dietary habits and exposure to harmful substances among individuals worldwide. Additionally, there is a growing awareness regarding diverse cancer treatment options among the global population, contributing to market expansion. Furthermore, the increasing adoption of cancer immunotherapies is driven by their ability to offer prolonged progression-free survival (PFS) and overall survival (OS) compared to traditional anti-tumor therapies. The availability and accessibility of medical insurance, alongside rising healthcare expenditure, are presenting attractive growth prospects for industry investors. Moreover, there is a growing demand for treatment approaches with fewer adverse effects, which aligns with the increasing approval of novel immunotherapies and fuels market growth. Government agencies and non-profit organizations in various countries are actively promoting the adoption of cancer immunotherapy through widespread awareness campaigns focused on cancer prevention. Lastly, the market benefits from ongoing technological advancements in cancer treatment therapies, which are enhancing the efficiency of disease management strategies. These factors collectively contribute to the positive growth trajectory of the cancer immunotherapy market in Japan.

Japan Cancer Immunotherapy Market Segmentation:

Therapy Type Insights:

Monoclonal Antibodies
Cancer Vaccines
Checkpoint Inhibitors
Immunomodulators
Others

Application Insights:

Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head and Neck Cancer
Others

End User Insights:

Hospitals
Cancer Research Centers
Clinics
Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan cancer immunotherapy market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan cancer immunotherapy market?
What is the breakup of the Japan cancer immunotherapy market on the basis of therapy type?
What is the breakup of the Japan cancer immunotherapy market on the basis of application?
What is the breakup of the Japan cancer immunotherapy market on the basis of end user?
What are the various stages in the value chain of the Japan cancer immunotherapy market?
What are the key driving factors and challenges in the Japan cancer immunotherapy?
What is the structure of the Japan cancer immunotherapy market and who are the key players?
What is the degree of competition in the Japan cancer immunotherapy market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Cancer Immunotherapy Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Cancer Immunotherapy Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Cancer Immunotherapy Market - Breakup by Therapy Type

6.1 Monoclonal Antibodies
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Cancer Vaccines
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 Checkpoint Inhibitors
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
6.4 Immunomodulators
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2019-2024)
- 6.4.3 Market Forecast (2025-2033)
6.5 Others
- 6.5.1 Historical and Current Market Trends (2019-2024)
- 6.5.2 Market Forecast (2025-2033)

7 Japan Cancer Immunotherapy Market - Breakup by Application

7.1 Lung Cancer
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Breast Cancer
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
7.3 Colorectal Cancer
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)
7.4 Melanoma
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2019-2024)
- 7.4.3 Market Forecast (2025-2033)
7.5 Prostate Cancer
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2019-2024)
- 7.5.3 Market Forecast (2025-2033)
7.6 Head and Neck Cancer
- 7.6.1 Overview
- 7.6.2 Historical and Current Market Trends (2019-2024)
- 7.6.3 Market Forecast (2025-2033)
7.7 Others
- 7.7.1 Historical and Current Market Trends (2019-2024)
- 7.7.2 Market Forecast (2025-2033)

8 Japan Cancer Immunotherapy Market - Breakup by End User

8.1 Hospitals
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Cancer Research Centers
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Clinics
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)
8.4 Others
- 8.4.1 Historical and Current Market Trends (2019-2024)
- 8.4.2 Market Forecast (2025-2033)

9 Japan Cancer Immunotherapy Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Services Offered
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Services Offered
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Services Offered
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Services Offered
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Services Offered
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Cancer Immunotherapy Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis